中文摘要：

目的探讨重组人粒细胞刺激因子（recombinant human-granulocyte colony sti mulating factor，rhG-CSF）和重组人血小板生成素（recombinant human-thrombopoietin，rhTPO）促进异基因造血干细胞移植后造血功能重建的作用。方法选取15例异基因造血干细胞移植患者，其中同胞间全相合移植6例，非血缘全相合移植7例，半相合移植2例，于移植后＋1d予以rhG-CSF（300μg/d）和rhTPO（15 000u/d）治疗，观察患者造血重建的时间和相关并发症发生情况。结果患者于移植＋15d（＋8～＋20d）N〉0.5×10^9/L，移植＋19d（＋11～＋23d）PLT〉30×10^9/L，提示造血功能重建。移植＋30d复查短串联重复序列（STR）检测，均提示重建造血为供者造血。随访至今，所有患者造血稳定重建。15例患者中10例出现感染、发热；15例患者均出现不同程度的皮下出血，多表现为皮肤淤点淤斑，2例患者出现鼻出血；3例患者在造血重建前夕出现全身骨痛。3例出现Ⅱ度以下急性移植物抗宿主病（GVHD），2例患者出现轻度的慢性GVHD。结论rhG-CSF联合rhTPO促进异基因造血干细胞移植后造血重建疗效肯定，减少移植感染、出血等并发症的发生率，缩短层流病房住院日，减少血小板、红细胞等血液制品的输入量，降低移植费用。

英文摘要：

Objective To explore the clinical effect of hematopoietic reconstitution in allo-hematopoietic stem cell transplant patients with leukemia accelerated by recombinant human-granulocyte colony stimulating factor （rhG-CSF） and recombinant human-thrombopoietin （rhTPO）. Methods Fifteen leukemia patients received rhG-CSF （300μg/d） and rhTPO （15 000u/d） from ld until WBC recovering to 4.0 ×10^99/L and platelet recovering to 75 ×10^99/L. Results The median days of neutrophile granulocyte up to 0.5 ×10^99/L were 15d and the median days of PLT up to 30 ×10^99/L were 19d. STR method display donor haemopoiesis on 30d. Some patients had fever, subcutaneous hemorrhage and nasal bleeding. Three patiens had ostalgia before hematopoietic reconstitution. Three patiens had Ⅰ / Ⅱ aGVHD and two patiens had slight cGVHD. Conclusion RhG-CSF and rhTPO administrtion after allo-HSCT can obviously accelerate the recovery of WBC and PLT, reduce the risk of infection and haemorrhage, and shorten the time of hospitalization.